Pyrvinium Pamoate

CHEMBL1908377 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1151.4 g/mol
LogP
Phase
4

Pyrvinium pamoate is the pamoate salt formulation of pyrvinium, an antiparasitic agent used for treatment of pinworm infections that also inhibits the Wnt/beta-catenin signaling pathway, making it of interest as an anticancer agent in pancreatic and other cancers. See pyrvinium for complete pharmacological details.

Peso Molecular

1151,4000 g/mol

TPSA

145,00 Ų

Áreas Terapêuticas

Mecanismo de Ação

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.O=C([O-])c1cc2ccccc2c(Cc2c(O)c(C(=O)[O-])cc3ccccc23)c1O

InChI

InChI=1S/2C26H28N3.C23H16O6/c2*1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h2*6-18H,1-5H3;1-10,24-25H,11H2,(H,26,27)(H,28,29)/q2*+1;/p-2

Molecular Formula

C75H70N6O6

HBD / HBA

2 / 8

Ligações Rotacionáveis

12

Átomos Pesados

87

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Pyrvinium pamoate is the pamoate salt formulation of pyrvinium, an antiparasitic agent used for treatment of pinworm infections that also inhibits the Wnt/beta-catenin signaling pathway, making it of interest as an anticancer agent in pancreatic and other cancers. See pyrvinium for complete pharmacological details.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Pyrvinium Pamoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1908377. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54680693. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.